Clinical trials: Patients with Multiple Sclerosis
Multiple Sclerosis, Clinically Isolated Syndrome
Autoimmune Intervention Mastery Course Study
The goal of this project is to critically evaluate the effectiveness of using an online program to improve diet and self-care in patients with multiple sclerosis (MS), clinically isolated syndrome (CIS), fibromyalgia, post acute…
- Conditions
- Multiple Sclerosis, Clinically Isolated Syndrome, Fibromyalgia, Post Acute Sequelae of COVID-19
- Trial name
- AIM (NCT05057676)
- Testing
- Immediate Autoimmune Intervention Mastery Course (AIM), Immediate Question and Answer sessions. (AIM Q and A sessions), Delayed Autoimmune Intervention Mastery Course (delayed AIM course)
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Terry L. Wahls
Multiple Sclerosis
Real-Life Outcomes of Multiple Sclerosis Treatment With Rebif
The purpose of this study is to determine whether Rebif has an impact on employment status, quality of life and cognition.
- Trial name
- RLO (NCT02377323)
- Testing
- MACFIMS, MSQoL-54
- Where
- Canada
- Volunteers
- 296 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Multiple Sclerosis
Plantar Pressure Distribution in Patient With Multiple Sclerosis
Fifty patients who were referred to receive physiotherapy and 20 healthy volunteers will be participants of the study.Participants with multiple sclerosis will evaluate with the following assessment tools: Modified Ashworth scale…
- Trial name
- NCT02947906
- Testing
- No intervention
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Hacettepe University
Multiple Sclerosis
Prospective Longitudinal Monocentric Study to Evaluate the Syde® Digital Endpoint in Patients With Multiple Sclerosis
The study aims to assess the validity of real-world activity monitoring by the Syde® wearable device in subjects with multiple slclerosis.
- Trial name
- NHS-MS-EGYPT (NCT06346704)
- Testing
- Digital HealthTechnology
- Where
- Egypt
- Volunteers
- 86 people
- Sponsor
- SYSNAV
Multiple Sclerosis
Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
This study assessed the safety, tolerability and efficacy of two doses of oral fingolimod compared to placebo on efficacy parameters in patients with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- FREEDOMS II (NCT00355134)
- Testing
- Fingolimod
- Where
- 112 sites in United States, Australia and 6 more
- Volunteers
- 1,083 people
- Sponsor
- Novartis
Multiple Sclerosis
WOE of Anti-CD20 Therapies
The nature, intensity, and prevalence of this wearing-off effect remain poorly understood. To our knowledge, there is no consensus in the literature on what symptoms constitute a wearing-off effect, nor is there a single…
- Trial name
- NCT06121349
- Testing
- ocrelizumab, ofatumumab
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Lower Urinary Tract Symptoms
Central Nervous System Changes Following OnabotulinumtoxinA Injection in the Bladder
The purpose of this research study is to evaluate higher neural changes following intra-detrusor injection of Onabotulinumtoxin-A (BTX-A) in patients with Multiple Sclerosis (MS).
- Conditions
- Multiple Sclerosis, Lower Urinary Tract Symptoms, Neurogenic Bladder, Detrusor, Overactive
- Trial name
- NCT03033355
- Testing
- Intra-detrusor injection of Onabotulinumtoxin-A
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The Methodist Hospital Research Institute
Relapsing-remitting Multiple Sclerosis
Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)
The purpose of this single visit extension study is to explore immune status in RRMS patients treated for at least 48 months with fingolimod.
- Trial name
- NCT02720107
- Testing
- fingolimod
- Where
- 26 sites in Germany
- Volunteers
- 133 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Pain
Effectiveness of a Mindfulness-Based Intervention for Pain Management in Patients With Multiple Sclerosis (MPIMS).
The goal of this clinical trial is to evaluate whether a mindfulness-based intervention is effective for reducing pain in adults with multiple sclerosis.
- Conditions
- Multiple Sclerosis, Pain, Pain Management
- Trial name
- MPIMS (NCT07741864)
- Testing
- Mindfulness-based intervention, Educational intervention
- Where
- Spain
- Volunteers
- 84 people
- Sponsor
- Hospital Universitario Virgen Macarena
Tuberous Sclerosis Complex
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
The purpose of this study is to evaluate the long-term safety in patients with TSC and refractory seizures who are currently receiving everolimus treatment in the Novartis-sponsored EXIST-3 study and who are determined to be…
- Trial name
- NCT02962414
- Testing
- everolimus
- Where
- 67 sites in United States, Australia and 16 more
- Volunteers
- 206 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
The study will evaluate the physical impact of MS from participant's perspective, provide continued access to ocrelizumab and assess the safety and tolerability of ocrelizumab.
- Trial name
- OleroMAX (NCT06675955)
- Testing
- Ocrelizumab
- Where
- 56 sites in Bulgaria, France and 4 more
- Volunteers
- 500 people
- Sponsor
- Hoffmann-La Roche
Relapsing-remitting Multiple Sclerosis
Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b
The "SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis - Follow up Study" is the follow up study of the "SWiss Atorvastatin and Interferon Beta-1b Trial In Multiple Sclerosis (SWABIMS)" (see…
- Trial name
- NCT01111656
- Testing
- Interferon beta-1b group, Interferon beta-1b/Atorvastatin group
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Neurogenic Bladder Dysfunction
Stimulation of Acupuncture Points in Female Patients With Multiple Sclerosis and Neurogenic Bladder Dysfunction
Electrical vs. manual stimulation: The study compares two types of acupuncture - one using mild electrical currents and one using just manual no-needle techniques in the treatment of urinary bladder disfunction.
- Trial name
- ACULUTS (NCT07183683)
- Testing
- group 1: electrical stimulation of acupuncture points plus routine care, group 2: acupressure plus routine care
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Charite University, Berlin, Germany
Multiple Sclerosis
Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study
The planned study will be a prospective, non-interventional, observational cohort study using the structure of a registry. Medication usage behavior will be observed for 6 months, while documentation behavior on the wellness…
- Trial name
- PROmyBETAapp (NCT03134573)
- Testing
- Interferon beta-1b (Betaferon, BAY86-5046), Betaconnect auto-injector, myBETAapp
- Where
- Germany
- Volunteers
- 96 people
- Sponsor
- Bayer
Primary Progressive Multiple Sclerosis
Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS
The goal of this non-interventional, observational study is to learn if cortical plexus enhancement in patients with primary progressive multiple sclerosis occurs in response to the autoimmune inflammatory process.
- Trial name
- ORATORIO-CP (NCT05974852)
- Testing
- Ocrelizumab
- Where
- United States
- Volunteers
- 732 people
- Sponsor
- State University of New York at Buffalo
Pain, Pain Syndrome
Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis
Over the last years a rising medical need for treatment of chronic pain was identified. Based on previous findings indicating the pain modulating effects of cannabinoids in chronic pain disorders, this clinical trial investigates…
- Conditions
- Pain, Pain Syndrome, Pain, Chronic, Chronic Pain
- Trial name
- NCT06071949
- Testing
- Adezunap
- Where
- Germany
- Volunteers
- 558 people
- Sponsor
- Apurano Pharmaceuticals GmbH
Relapsing Remitting Multiple Sclerosis
Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx
This is for a randomized clinical trial (RCT) to determine if the combined use of interferon beta-1a (IFN) and glatiramer acetate (GA) is a measurably better therapy than either agent used individually in patients with…
- Trial name
- NCT00211887
- Testing
- Interferon beta 1-a, glatiramer acetate
- Where
- 71 sites in United States, Canada
- Volunteers
- 1,008 people
- Sponsor
- Fred Lublin
Relapsing-Remitting Multiple Sclerosis, Urinary Incontinence
Guided Versus Non-guided Pelvic Floor Exercises for Urinary Incontinence in Relapsing-Remitting Multiple Sclerosis
The aim of the study is to evaluate the effectiveness of guided versus non guided pelvic floor exercises for urinary incontinence in patients with Relapsing-Remitting Multiple Sclerosis
- Trial name
- NCT03000647
- Testing
- Pelvic floor exercises guided by a physiotherapist, Non guided pelvic floor exercises
- Where
- Spain
- Volunteers
- 48 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Relapsing Multiple Sclerosis
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
This randomized, double-blind, double-dummy, parallel-group study will evaluate the efficacy and safety of ocrelizumab in comparison with interferon beta-1a (Rebif) in participants with relapsing multiple sclerosis.
- Trial name
- NCT01412333
- Testing
- Interferon beta-1a, Ocrelizumab
- Where
- 165 sites in United States, Argentina and 22 more
- Volunteers
- 835 people
- Sponsor
- Hoffmann-La Roche
Relapsing Remitting Multiple Sclerosis
Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy
This study assessed the efficacy of fingolimod in patients with short duration relapsing-remitting multiple sclerosis who had not been previously treated with disease-modifying therapies (DMTs), versus patients with the same…
- Trial name
- EARLiMS (NCT01498887)
- Testing
- Fingolimod (FTY720)
- Where
- 47 sites in Australia, Spain
- Volunteers
- 347 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.